We are live on ! Find out more
KAM

Krensavage Asset Management Portfolio holdings

AUM $256M
1-Year Est. Return 69.63%
This Fund
S&P 500
This Quarter Est. Return
-7.91%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$260M
AUM Growth
-$47.7M
Cap. Flow
-$22.3M
Cap. Flow %
-8.56%
Top 10 Hldgs %
100%
Holding
11
New
1
Increased
5
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$28.7M
2
ENTA icon
Enanta Pharmaceuticals
ENTA
+$1.43M
3
BIIB icon
Biogen
BIIB
+$35.9K
4
GILD icon
Gilead Sciences
GILD
+$31.2K
5
ELAN icon
Elanco Animal Health
ELAN
+$23.1K

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$39.7M
2
MCK icon
McKesson
MCK
+$11.3M
3
UTHR icon
United Therapeutics
UTHR
+$822K
4
IVC
Invacare Corporation
IVC
+$598K
5
SRGA
Surgalign Holdings, Inc. Common Stock
SRGA
+$97.6K

Sector Composition

Rank Sector Weight
1 Healthcare 96.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$25.8B
$43.1M 16.54%
540,094
-10,205
-2% -$822K
BIIB icon
2
Biogen
BIIB
$30B
$41.1M 15.8%
176,710
+154
+0.1% +$35.9K
MCK icon
3
McKesson
MCK
$100B
$40.1M 15.39%
293,297
-80,000
-21% -$11.3M
GILD icon
4
Gilead Sciences
GILD
$162B
$35M 13.43%
551,715
+478
+0.1% +$31.2K
ENTA icon
5
Enanta Pharmaceuticals
ENTA
$366M
$30M 11.51%
498,874
+19,298
+4% +$1.43M
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$25M 9.59%
+255,000
New +$28.7M
ELAN icon
7
Elanco Animal Health
ELAN
$13.2B
$23.7M 9.11%
892,620
+769
+0.1% +$23.1K
SRGA
8
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$11.1M 4.26%
129,677
-914
-0.7% -$97.6K
IVC
9
DELISTED
Invacare Corporation
IVC
$9.19M 3.53%
1,224,761
-106,648
-8% -$598K
AVNS
10
DELISTED
Avanos Medical
AVNS
$2.23M 0.85%
59,429
+51
+0.1% +$1.95K
AMGN icon
11
Amgen
AMGN
$208B
– –
-215,402
Closed -$39.7M

Similar funds

CIA
Corigliano Investment Advisers Raleigh, North Carolina $256M AUM 54.89% 1-Year Est. Return
2
2Xideas Kusnacht, Switzerland $255M AUM 0.46% 1-Year Est. Return
CIM
Caldwell Investment Management Toronto, Ontario, Canada $255M AUM 36.87% 1-Year Est. Return
JFG
Juno Financial Group Richmond, Virginia $255M AUM
PIP
Palisades Investment Partners Santa Monica, California $255M AUM 50.52% 1-Year Est. Return
LRIC
Long Road Investment Counsel Kalamazoo, Michigan $255M AUM 12.85% 1-Year Est. Return
GAMC
Garner Asset Management Corp Plano, Texas $255M AUM 22.93% 1-Year Est. Return
TIA
Tiemann Investment Advisors Menlo Park, California $255M AUM 21.35% 1-Year Est. Return

Krensavage Asset Management's Q3 2019 Portfolio in Review

As of Q3 2019, Krensavage Asset Management held 11 positions worth $260M, down 15% from $308M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Krensavage Asset Management withdrew a net $22.3M in Q3 2019, closing 1 position and reducing 4 holdings. Its most notable exit was Amgen, an estimated $39.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier.

Against the trend, Krensavage Asset Management opened a new position in Alexion Pharmaceuticals worth $25M.

  • Krensavage Asset Management's largest Q3 2019 buy was Alexion Pharmaceuticals: 255,000 shares worth $25M.
  • Krensavage Asset Management added most to Enanta Pharmaceuticals in Q3 2019, an estimated $1.43M increase.
  • Krensavage Asset Management's biggest Q3 2019 reduction was McKesson, cutting an estimated $11.3M.
  • Krensavage Asset Management fully exited Amgen in Q3 2019, selling an estimated $39.7M.
  • Krensavage Asset Management's ten largest holdings make up 100% of its $260M portfolio in Q3 2019.
  • Krensavage Asset Management opened 1 new position and closed 1 in Q3 2019.
  • Krensavage Asset Management's portfolio value fell 15% quarter-over-quarter to $260M.

Based on Krensavage Asset Management's 13F filing for Q3 2019, filed 15 Nov 2019.